Adaptimmune Therapeutics ADR (NASDAQ:ADAP) Share Price

Company Profile

Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A10 T-cell therapy, NON-SMALL CELL LUNG CANCER, AFP SPEAR T-cell, MAGE-A4 SPEAR T-cell therapy and NY-ESO SPEAR T-cell for multiple cancer types.Adaptimmune Therapeutics PLC along with its subsidiaries is a clinical-stage biopharmaceutical company. It is engaged in novel cancer immunotherapy products based on its T-cell receptor platform.